Lifecore Biomedical (LFCR) Stock Price
Lifecore Biomedical Price
Revenue at Lifecore Biomedical has contracted by 2.5% per year over the past 19 years to 129.46 M USD. Earnings per share have declined at 6.4% per year over the last 17 years. Lifecore Biomedical's net margin stands at -23.8%, up from -52.4% several years earlier. Analysts set a median price target of 6.50 USD, implying 1.0% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus.
Lifecore Biomedical stock price
Lifecore Biomedical business model & stock analysis
Frequently asked questions about Lifecore Biomedical
The business model of Landec Corp revolves around developing and commercializing innovative health and wellness solutions. Landec Corp primarily focuses on creating and selling differentiated products through two business segments: Curation Foods and Lifecore Biomedical. Curation Foods offers a wide range of plant-based foods, such as fresh packaged salads, vegetables, and fruit snacks, while Lifecore Biomedical specializes in developing and manufacturing various biomaterials and products for medical applications. With a commitment to sustainability and healthy living, Landec Corp aims to provide customers with high-quality, environmentally friendly products that enhance overall well-being.
Landec Corp is primarily active in the food packaging and biomaterial industries.
The main competitors of Landec Corp in the market include companies such as Archer-Daniels-Midland Company, Cargill Incorporated, and Ingredion Incorporated.
Landec Corp is a renowned company with a rich history and background. Founded in 1986, Landec Corp has grown to become a leading lifesciences company specializing in innovative health and wellness solutions. With headquarters in Menlo Park, California, Landec Corp focuses on the development and commercialization of differentiated products in various industries. The company is dedicated to solving challenges in agriculture, food, and biomedical materials through its proprietary technologies. Landec Corp has built a strong reputation for delivering high-quality, sustainable products, and its commitment to innovation has propelled its growth and success in the market.
Landec Corp has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Lifecore Biomedical in 2013, which expanded their presence in the healthcare industry. Another important achievement was the introduction of the patented BreatheWay technology, which extended the shelf life of fresh produce. In addition, Landec Corp has successfully established strategic partnerships with major retailers, such as Walmart and Whole Foods, further enhancing their market reach. These accomplishments have solidified Landec Corp's position as a leading player in the technology-driven food and biomedical markets.
Landec Corp is primarily present in the United States.
Landec Corp represents a set of core values and a corporate philosophy focused on innovation, sustainability, and growth. The company prioritizes delivering innovative solutions and products that address the evolving needs of its customers. Landec Corp aims to contribute positively to the environment and society by employing sustainable practices across its operations. It actively invests in research and development to stay at the forefront of technology advancements, fostering growth opportunities. Through its commitment to operational excellence and customer satisfaction, Landec Corp strives to establish itself as a trusted leader in its industry.
Analysts currently set an average price target of 6.50 USD for the Lifecore Biomedical stock (median: 6.50 USD), implying +1.0 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Lifecore Biomedical stock: 8 recommend buying, 3 holding and 0 selling.
Converted at the current exchange rate, the Lifecore Biomedical share trades at 5.74 EUR (6.43 USD).
The Lifecore Biomedical share (LFCR) is listed on 2 stock exchanges, including: NASDAQ (LNDC), Frankfurt (LDE.F).
Landec Corporation is a company specialized in the development and marketing of innovative and sustainable products in various areas. Its main divisions are Lifecore Biomedical and Curation Foods. Lifecore Biomedical produces medical devices and technologies for the field of regenerative medicine, such as implants, artificial joints, and other medical instruments. These products are developed and manufactured in collaboration with medical professionals, using advanced materials and technologies. On the other hand, Curation Foods operates in the food industry, offering different types of fruits and vegetables produced in a healthy and sustainable way. Some of Landec Corp's products include "Eat Smart" products from Curation Foods, which offer various vegetable and fruit salads as well as ready-to-eat meals. The company combines sustainable agriculture, modern processing methods, and innovative packaging design. Another product is IntelliBond, a special micronutrient additive for animal feed. Through patented technology, IntelliBond is designed to be better absorbed by animals, effectively preventing nutrient deficiencies. Landec Corp's business model aims to develop and market sustainable products that improve the health of people and animals while preserving the environment. The company emphasizes close collaboration between scientists, technology experts, and other professionals to develop innovative solutions tailored to the needs of customers and consumers. In addition, the company strives to integrate sustainability principles into its production and supply chains to reduce environmental impacts and conserve resources. This includes the use of recyclable materials and the promotion of projects to improve agriculture and environmental protection. Overall, Landec Corp offers a wide range of innovative and sustainable products in various sectors, focusing on the needs of customers and consumers. The company values sustainability, quality, and innovation, and relies on close collaboration among professionals from different fields to develop sustainable solutions.
The revenue of Lifecore Biomedical is 129.46 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Lifecore Biomedical is -30.79 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lifecore Biomedical is currently -7.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lifecore Biomedical stock.
The price-to-sales ratio (P/S) of Lifecore Biomedical is currently 1.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lifecore Biomedical stock.
The Eulerpool Quality Score for Lifecore Biomedical is 2/10.
The ISIN of Lifecore Biomedical is US5147661046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lifecore Biomedical is 899376. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lifecore Biomedical is LFCR. The ticker symbol is used to trade Lifecore Biomedical shares on the stock exchange.
Lifecore Biomedical stock
Lifecore Biomedical Peer Group
Lifecore Biomedical Ticker
Lifecore Biomedical FIGI
All fundamentals and in-depth analysis of Lifecore Biomedical
Our stock analysis for Lifecore Biomedical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lifecore Biomedical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.